How long does chemotherapy for myelodysplastic syndromes last?
Sep 23, 2025
Source: Cainiu Health
Dr. Liu Feng
Introduction
In general, the chemotherapy cycles for myelodysplastic syndromes are determined based on the patient's condition, risk stratification, and treatment response, typically requiring 3–6 courses, with specific plans dynamically evaluated and adjusted by the physician. During chemotherapy, patients need regular follow-up tests including complete blood counts and bone marrow examinations, and should closely monitor their physical responses. Any symptoms such as fever, worsening fatigue, or signs of bleeding should be promptly reported.
In general, the chemotherapy cycle for myelodysplastic syndromes (MDS) should be determined based on the patient's condition, risk stratification, and treatment response. Typically, 3–6 treatment cycles are required, with specific plans dynamically evaluated and adjusted by physicians. The detailed analysis is as follows:
For patients with low-risk or intermediate-low-risk MDS whose condition is relatively stable, without severe cytopenia or organ involvement, who respond well to chemotherapy, show gradual recovery of bone marrow hematopoietic function, normalization of blood test indicators, and no serious complications such as severe infection or bleeding, the chemotherapy course may generally be controlled within approximately 3 months after dynamic evaluation by physicians. Afterwards, maintenance therapy or regular monitoring may be sufficient.
For patients classified as intermediate-high-risk or high-risk, whose disease progresses rapidly, showing significant signs of bone marrow failure, or who initially respond poorly to chemotherapy and require regimen adjustments, or those who develop notable complications during treatment necessitating temporary suspension for observation until physical condition improves before resuming therapy, the chemotherapy duration may need to be extended up to 6 months following comprehensive physician assessment. This allows more effective disease control and reduces the risk of disease progression.
During chemotherapy, patients should undergo regular follow-up tests including complete blood counts and bone marrow examinations, and closely monitor their physical responses. Any symptoms such as fever, worsening fatigue, or signs of bleeding should be promptly reported to the doctor. Additionally, patients should maintain adequate nutritional support, practice good personal hygiene to prevent infections, and strictly adhere to medical instructions throughout treatment—chemotherapy regimens must not be altered or discontinued without physician guidance.
